ABBV Jan 2025 145.000 call
| Previous close | 20.99 |
| Open | 21.31 |
| Bid | 20.05 |
| Ask | 21.75 |
| Strike | 145.00 |
| Expiry date | 2025-01-17 |
| Day's range | 21.31 - 21.31 |
| Contract range | N/A |
| Volume | |
| Open interest | 163 |
- PR Newswire
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports continued innovation and provides cutting-edge products and technologies to help practitioners and patients' aesthetics needs today and for the future.
- Motley Fool
3 Reasons to Buy AbbVie and 2 Reasons Not to Buy
2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion-plus in revenue in 2022.
- Motley Fool
Want Safety and Growth in 2023? Try These Dividend Stocks.
Last year was a tough one for most companies and investors. The three major indexes touched bear territory. And even the strongest of companies saw their share prices slip. Everyone is hoping 2023 will bring better days.
